Cannabidiol.

Cannabidiol dissolves in lipid, not water, so a medium-chain triglyceride carrier keeps it in solution through the gut lumen and into mixed micelles. Most consumer tinctures are formulated in MCT for exactly this reason. The effect is on how much reaches circulation, an absorption parameter rather than an outcome.

Long-chain fats stimulate bile release and chylomicron formation, and lipophilic cannabinoids partition into that stream. Co-dosing with an oil-based omega-3 softgel is a practical way to take cannabidiol with fat. This concerns uptake, not any clinical endpoint.

Piperine slows first-pass metabolism broadly, so a piperine-containing formula can raise cannabinoid exposure beyond what the label dose suggests. That cuts both ways and is worth flagging rather than selling. Anyone taking medicines cleared by CYP3A4 or CYP2C19 should raise the combination with a clinician.

Curcumin and cannabidiol are commonly stacked in the same oil base and share a metabolic bottleneck. The interaction is pharmacokinetic, affecting blood levels rather than any measured endpoint. Read it as mechanistic rather than clinical.

Sustained St Johns wort intake pushes hepatic and intestinal CYP3A4 upward, and cannabidiol is metabolised through that isoform. The expected direction is lower cannabidiol exposure at the same dose. This is an anti-synergy and belongs on a caution list, not a stack card.

Night-time cannabidiol products routinely carry melatonin, and both can add to next-morning grogginess in sensitive users. No combination trial supports a specific joint dose. The pairing is formulation convention with a plausible additive direction.

Valerian acts on GABAergic tone and cannabidiol has its own calming profile, so the combined effect on alertness can exceed either alone. Driving and machinery caution applies. The additive direction is the claim, not a magnitude.

Chamomile apigenin binds benzodiazepine-site receptors in laboratory work, and the two show up together in sleep formulations. Nothing has measured the pair in people. Confidence stays low on purpose.

L-theanine raises alpha-band cortical activity and modulates glutamate and GABA signalling; cannabidiol works through a separate, non-CB1-agonist profile. Non-overlapping targets are why they are formulated together. No trial has tested the combination.

Caffeine raises arousal while cannabidiol is used to settle it, so the two pull against each other in the same product. Some users report the pairing smooths caffeine jitter, which is subjective and unmeasured here. Flagged as an opposing-direction combination rather than a benefit.

Cannabinoids oxidise on exposure to air and light, and a tocopherol in the carrier oil delays that loss. The role is shelf stability of the oil, nothing physiological. Vitamin E acetate in vape products is a separate matter and not what an oral oil uses.

The in vitro inhibition is well described; how much it moves cannabidiol levels in a person is not established. Flagged so a formulator knows the overlap exists. Read it as mechanistic.

Ashwagandha acts on the hypothalamic-pituitary-adrenal axis while cannabidiol does not. Products pair them for a stress-support positioning. Nothing has measured the two together.